The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.
OBJECTIVE
To examine the association between the sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer.


METHODS
Meta-analysis of case-control studies using a random effects model. The "Main outcome measure" was the odds ratio for the risk of lung cancer, using extensive metabolisers as the reference group.


RESULTS
Thirteen studies were identified. The studies were too heterogeneous to be pooled the size of the odds ratio increased with the sample size. When the analysis was restricted to the largest studies, there was no difference in risk between poor and extensive metabolisers (odds ratio 0.95, 95% confidence interval 0.68-1.33).


CONCLUSIONS
No association was found between the CYP2D6 oxidation polymorphism and lung cancer risk when sample size bias was taken into account.
Christensen
P M
PM
Department of Clinical Pharmacology, Odense University, Denmark.
Gøtzsche
P C
PC
Brøsen
K
K
D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D003647:Debrisoquin / Q000378:metabolism*; D004198:Disease Susceptibility; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology / Q000235:genetics*; D016017:Odds Ratio; D010084:Oxidation-Reduction; D010641:Phenotype; D011110:Polymorphism, Genetic; D012307:Risk Factors; D013034:Sparteine / Q000378:metabolism*
D013034:Sparteine; D019389:Cytochrome P-450 CYP2D6; D003647:Debrisoquin